NCT05041504Completed
A Web-based Peer Navigation Program for Men With Prostate Cancer
A Web-based Peer Navigation Program for Men With Prostate Cancer: A Hybrid Effectiveness-Implementation Trial
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
One in nine Canadian men will be diagnosed with prostate cancer (PC) in their lifetime. Although all treatment options can be effective in controlling the disease, treatment side effects such as problems with erections and controlling the bladder can significantly affect men's quality of life. Many men with PC say they do not get relevant information and emotional support, and experience gaps in care when dealing with these difficult issues. Previous studies have shown that cancer patient navigation improves access to care and support, and reduces healthcare costs. The investigators developed True North Peer Navigation - a peer navigation program for men with PC and a peer navigator training course. Men are matched online with a trained peer navigator who provides practical information and emotional support through the cancer journey. A pilot evaluation showed that it is highly acceptable to patients and peer navigators, and improves patient quality of life, social support and ability to manage their health. In this study, the investigators will conduct a randomized controlled trial of the True North Peer Navigation program in cancer centres in Ontario, British Columbia and Nova Scotia. Patients will be randomly assigned to receive True North Peer Navigation or an active wait list control consisting of usual care with access to information on the True North Peer Navigation website. The investigators will evaluate the effect of the True North Peer Navigation program on patient outcomes such as their ability to take a more active role in their health, quality of life, social support and use of health care services. In addition, the investigators will evaluate how True North Peer Navigation was implemented, the experiences patients and peer navigators, the factors that make it easier or harder for people to deliver the program to patients in different settings, as well as the cost of delivering the program, which will help us learn how to spread the program across the country.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 184 (actual)
- First submitted
- 10 Aug 2021
- Start date
- 13 May 2022
- Primary completion date
- 18 Mar 2024
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT05041504
What you commit to
- Study type: Interventional
- Participants enrolled: 184
- From 13 May 2022 to the primary completion date, 18 Mar 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is receiving palliative care.
Other illness
- Has been diagnosed with advanced metastatic disease.
Other
- Is not willing to be randomized.
Who the study is looking for
- Has been diagnosed with local, locally advanced or stable metastatic PC.
- Has recently completed treatment within 3 months
- Has an email address OR is willing to create one.
- Can read and speak English.
Sex: Male · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Queen Elizabeth II, Health Sciences Centre Coordinator of this site? Confirm its status | Halifax | Canada | Unknown status |
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| BC Cancer - Vancouver Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.